Tiludronate infusion in horses previously submitted to bone scintigraphy
This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the stu...
Guardado en:
Autores principales: | , , |
---|---|
Lenguaje: | English |
Publicado: |
Facultad de Ciencias Veterinarias, Universidad Austral de Chile
2016
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:scielo:S0301-732X2016000300010 |
---|---|
record_format |
dspace |
spelling |
oai:scielo:S0301-732X20160003000102016-12-27Tiludronate infusion in horses previously submitted to bone scintigraphyDörner,CARick,MCJudy,CE horse bisphosphonates tiludronate bone scintigraphy This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the study. Fifteen horses received a dose of technetium (0.3 mCi/kg), MDP (20 mg; medronate) and another fifteen horses received technetium (0.3 mCi/kg), MDP (20 mg), and furosemide (1 mg/kg). Then, 24 to 36 hours after the bone scintigraphy, eight horses were selected and received tiludronate (500 mg in 5L of 0.9% NaCl). Blood samples were collected 15 minutes prior, 24 and 48 hours after the treatment and a chemistry panel was assayed on the day of collection. Serum chemistry values were not significantly different between horses receiving tiludronate and those in both control groups. Additionally, one horse showed mild transient signs of colic recorded as pacing and stretching in the stall after 3 hours the injection of the tiludronic acid. The results suggest that tiludronate can be administered safely as one single dose in horses having undergone recent bone scintigraphy without additional complications or detrimental effect other than those previously described for the drug.info:eu-repo/semantics/openAccessFacultad de Ciencias Veterinarias, Universidad Austral de ChileArchivos de medicina veterinaria v.48 n.3 20162016-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010en10.4067/S0301-732X2016000300010 |
institution |
Scielo Chile |
collection |
Scielo Chile |
language |
English |
topic |
horse bisphosphonates tiludronate bone scintigraphy |
spellingShingle |
horse bisphosphonates tiludronate bone scintigraphy Dörner,CA Rick,MC Judy,CE Tiludronate infusion in horses previously submitted to bone scintigraphy |
description |
This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the study. Fifteen horses received a dose of technetium (0.3 mCi/kg), MDP (20 mg; medronate) and another fifteen horses received technetium (0.3 mCi/kg), MDP (20 mg), and furosemide (1 mg/kg). Then, 24 to 36 hours after the bone scintigraphy, eight horses were selected and received tiludronate (500 mg in 5L of 0.9% NaCl). Blood samples were collected 15 minutes prior, 24 and 48 hours after the treatment and a chemistry panel was assayed on the day of collection. Serum chemistry values were not significantly different between horses receiving tiludronate and those in both control groups. Additionally, one horse showed mild transient signs of colic recorded as pacing and stretching in the stall after 3 hours the injection of the tiludronic acid. The results suggest that tiludronate can be administered safely as one single dose in horses having undergone recent bone scintigraphy without additional complications or detrimental effect other than those previously described for the drug. |
author |
Dörner,CA Rick,MC Judy,CE |
author_facet |
Dörner,CA Rick,MC Judy,CE |
author_sort |
Dörner,CA |
title |
Tiludronate infusion in horses previously submitted to bone scintigraphy |
title_short |
Tiludronate infusion in horses previously submitted to bone scintigraphy |
title_full |
Tiludronate infusion in horses previously submitted to bone scintigraphy |
title_fullStr |
Tiludronate infusion in horses previously submitted to bone scintigraphy |
title_full_unstemmed |
Tiludronate infusion in horses previously submitted to bone scintigraphy |
title_sort |
tiludronate infusion in horses previously submitted to bone scintigraphy |
publisher |
Facultad de Ciencias Veterinarias, Universidad Austral de Chile |
publishDate |
2016 |
url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010 |
work_keys_str_mv |
AT dornerca tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy AT rickmc tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy AT judyce tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy |
_version_ |
1718437970683363328 |